Melinta Therapeutics Announces Appointment of Susan Blum as Chief Financial Officer

Melinta Therapeutics, LLC (“Melinta”), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, announces the appointment of Susan Blum as Chief Financial Officer, effective July 1, 2021.

Ms. Blum has served as Melinta’s interim CFO, under the leadership of President and Chief Executive Officer Christine Ann Miller, since March 31, 2021, and she has been an integral leader on Melinta’s finance and accounting teams since 2016. Ms. Blum has a proven track record of strengthening and executing corporate financial strategy, efficiencies and controls for Melinta as well as diverse companies prior to Melinta.

“Susan is a seasoned finance executive and our trusted partner, with extensive knowledge about our company, products and markets. I’m both proud and excited to welcome her as our CFO to help lead our company forward with sustainable growth,” Ms. Miller said. “As we continue to build a legendary future, her experience, as well as her enthusiasm and dedication to Melinta, will be an incredible asset.”

Before joining Melinta, Ms. Blum held leadership positions in finance and accounting at Textura, Orbitz Worldwide, Facet Biotech and PDL BioPharma. In these roles, some of her notable experience includes directing global financial processes, leading accounting functions through dynamic business conditions, including initial and secondary public offerings, and directing financial reporting and integration activities for mergers and acquisitions.

“I’m honored to lead Melinta’s financial team and operations at this exciting moment in the company’s journey,” Ms. Blum said. “Melinta is truly unparalleled in passion and purpose, and I’m excited to continue to work with Christine and the rest of the team toward financial sustainability while staying grounded in what matters most — the patients we serve.”

About Melinta Therapeutics

Melinta Therapeutics, LLC provides innovative therapies to people impacted by acute and life-threatening illnesses. Our portfolio currently includes five commercial-stage antibiotics: Baxdela® (delafloxacin), Kimyrsa™ (oritavancin), Minocin® (minocycline) for Injection, Orbactiv® (oritavancin), and Vabomere® (meropenem and vaborbactam). With an unsurpassed commitment to providers and the patients they serve, we work to ensure that all people who need our therapies can receive them. We focus our expanding portfolio on serving patients with an unmet need because that’s how we make the most meaningful impact. At Melinta, we’re visionaries dedicated to innovation while staying grounded in what matters most: patients. Visit www.melinta.com for more information.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210629005251/en/